Czechia· CZ-0209414
ZAVICEFTA
A ceftazidim und beta-lactamase-inhibitor product containing ceftazidime pentahydrate + avibactam sodium, registered in Czechia by Pfizer Ireland Pharmaceuticals Unlimited Company, Ringaskiddy. The same ATC class is registered in 10 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Ceftazidim und beta-lactamase-inhibitor is registered in 10 of 19 countries.
Countries holding a registration under ATC J01DD52 (ceftazidim und beta-lactamase-inhibitor), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 7 of them publish a price we can compare per daily dose
Ceftazidim und beta-lactamase-inhibitor · ATC J01DD52
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of ceftazidim und beta-lactamase-inhibitor costs, country by country.
Normalised to the WHO defined daily dose (6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ceftazidim und beta-lactamase-inhibitor · price per daily dose (6 g)
USD · FX 28 Sept 2026
- CH Switzerland$407.92
The record
At a glance
SÚKL (Czech Republic)- Active substance
- CEFTAZIDIME PENTAHYDRATE + AVIBACTAM SODIUM
- Manufacturer
- Pfizer Ireland Pharmaceuticals Unlimited Company, Ringaskiddy
- Country
- Czechia (CZ)
- ATC code
- J01DD52
- ATC class
- Ceftazidim und Beta-Lactamase-Inhibitor
- Defined daily dose
- 6 g, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ceftazidim und beta-lactamase-inhibitor in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandZaviceftaPfizer Ireland Pharmaceuticals
- SpainZAVICEFTA 2 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONPfizer Ireland Pharmaceuticals Unlimited Company
- FinlandZaviceftaOrifarm Oy
- United StatesAVYCAZAllergan, Inc.
- IrelandZavicefta 2 g/0.5 g powder for concentrate for solution for infusionPfizer Ireland Pharmaceuticals
- SwitzerlandZavicefta, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungPfizer AG
- NetherlandsZAVICEFTA 2 g/0,5 g, poeder voor concentraat voor oplossing voor infusiePfizer Ireland Pharmaceuticals, Operations Services Group
- NorwayZaviceftaPfizer Ireland Pharmaceuticals Unlimited Company
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zavicefta
- Liechtenstein · Zavicefta
- Norway · Zavicefta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/52c72501-d494-4d53-823d-1965c1a5afd2 GET /v1/drugs/52c72501-d494-4d53-823d-1965c1a5afd2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INF PLV CSL",
"source": "sukl",
"strength": "2G/0,5G",
"pack_size": "10",
"substance": "CEFTAZIDIME PENTAHYDRATE + AVIBACTAM SODIUM",
"cz_kod_sukl": "0209414",
"product_type": "CH",
"substance_codes": "4988,21084",
"registration_state": "R",
"registration_number": "EU/1/16/1109/001"
}See everything about ceftazidim und beta-lactamase-inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.